Skip to main content
. 2017 Oct 17;7(19):4753–4762. doi: 10.7150/thno.21687

Figure 1.

Figure 1

The association between molecular mutational burden and treatment response. (A) alterations of 17 genes including ALK, BCL2, BRAF, CD74, CDKN2A, EML4, GSTP1, KIF5B, KRAS, MLH1, MTHFR, NRAS, RRM1, PIK3CA, SLC34A2, XPC and XRCC1 were frequently observed in 48 blood samples at baseline; (B) patients with PR had significantly lower molecular mutational burden of these genes than patients with SD. Although patients with SD appeared to have lower molecular mutational burden than those with PD, there was no statistically significant difference.